Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Market by Type, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
The global leukemia therapeutics market was valued at $7,818.63 million in 2021 and is estimated to reach $14,162.48 million by 2031, exhibiting a CAGR of 6.1% from 2022 to 2031.
Key factors driving the growth of the Leukemia therapeutics market include increase in people affected with leukemia, rise in awareness of diagnosis and treatment options for leukemia and high adoption of key strategies by key players.
For instance, in October 2020, AbbVie announced the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults for 75 years or older people.
Patients are becoming more aware of the available treatment options for leukemia, and are more likely to seek treatment, which has increased the demand for leukemia therapeutics. There is an increasing awareness among the general public about cancer and the available treatment options, which has led to more people seeking treatment for leukemia and drive the market growth.
In addition, availability of favorable government policies to improve the access to healthcare and encourage the R&D activities in oncology field boost the market growth. Moreover, development of more effective immunotoxins, alkylating drugs, monoclonal antibodies and multidrug resistant modulators has increased the adoption of leukemia therapeutics.
These therapeutics provide the long-lasting effects and improved efficacy in leukemia cell identification. Such advantages provided by the leukemia therapeutics propels the market growth in this region. Furthermore, rise in healthcare expenditure for the treatment of leukemia, which has boosted the growth of the market.
The market also offers growth opportunities to the key players in the market. Large number of companies involved in R&D and new product launches for leukemia are expected to drive the market growth. For instance, according to the data published by ClinicalTrials.gov, a randomized study was conducted to assess the efficacy and safety of Ublituximab in combination with TGR-1202 for patients of chronic lymphocytic leukemia (CLL). Leukemia pipeline products provide advanced efficacy and better patient outcomes than existing treatment.
This is attributed to the introduction of new drug classes, monoclonal antibodies, for leukemia. In addition, there are number of R&D activities conducted to develop different types of treatment by using combination of drugs to improve the patients' outcomes for leukemia. Thus, presence of drugs in pipeline is expected to provide lucrative opportunities for the growth of the market.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global leukemia therapeutics market analysis from 2021 to 2031 to identify the prevailing global leukemia therapeutics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the global leukemia therapeutics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global leukemia therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Others
By Drug Class
- Chemotherapy
- Targeted Therapy and Immunotherapy
By Distribution channel
- Hospital Pharmacies
- Drug Store and Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Amgen Inc.
- Bristol-Myers Squibb Company
- Lupin
- Sanofi
- Gilead Sciences, Inc.
- Takeda Pharmaceutical Company Limited
- Abbvie Inc
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- Novartis AG
Key Market Insights
- By type, the chronic lymphocytic leukemia segment was the highest revenue contributor to the market and is estimated to reach $5,778.23 million by 2031, with a highest CAGR.
- By drug class, the targeted therapy and immunotherapy segment dominated the global market in 2021.
- Based on distribution channel, the hospital pharmacies segment was the highest revenue contributor to the market with a CAGR of 5.9% during the forecast period. However, online providers segment is expected to grow at the highest CAGR during the forecast period.
- Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: LEUKEMIA THERAPEUTICS MARKET, BY TYPE
CHAPTER 5: LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS
CHAPTER 6: LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: LEUKEMIA THERAPEUTICS MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
For more information about this report visit https://www.researchandmarkets.com/r/xzhb4p
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
